Poster

Producing High-Quality, Therapeutically Relevant NK Cells Using A Large-Scale Biomanufacturing Platform

Source: BioCentriq
GettyImages-1383260152-NK_Cells

The LEAP™ platform offered by BioCentriq provides early-stage biotech companies with novel cell therapy candidates an avenue to leverage proven expertise and assets to reach patients in record time. Sponsors who leverage LEAP™ minimize up-front investment in process development, reduce risk, accelerate timelines, and lower the cost of IND-enabling studies and clinical production.

Data demonstrating the efficacy of BioCentriq's LEAP-NK™ platform can be found in this poster. The results of the study displayed in the poster suggest that BioCentriq’s LEAP-NK™ platform utilizing propriety feeder cell lines can enhance expansion of NK cells >12,000 fold.

access the Poster!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma